BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 24482120)

  • 1. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
    Thaler A; Artzi M; Mirelman A; Jacob Y; Helmich RC; van Nuenen BF; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Hendler T; Giladi N; Ben Bashat D;
    Mov Disord; 2014 May; 29(6):823-7. PubMed ID: 24482120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
    Brüggemann N; Hagenah J; Stanley K; Klein C; Wang C; Raymond D; Ozelius L; Bressman S; Saunders-Pullman R
    Mov Disord; 2011 Apr; 26(5):885-8. PubMed ID: 21312285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
    Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
    CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive profile of LRRK2-related Parkinson's disease.
    Srivatsal S; Cholerton B; Leverenz JB; Wszolek ZK; Uitti RJ; Dickson DW; Weintraub D; Trojanowski JQ; Van Deerlin VM; Quinn JF; Chung KA; Peterson AL; Factor SA; Wood-Siverio C; Goldman JG; Stebbins GT; Bernard B; Ritz B; Rausch R; Espay AJ; Revilla FJ; Devoto J; Rosenthal LS; Dawson TM; Albert MS; Mata IF; Hu SC; Montine KS; Johnson C; Montine TJ; Edwards KL; Zhang J; Zabetian CP
    Mov Disord; 2015 Apr; 30(5):728-33. PubMed ID: 25650144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.
    Gupte M; Alcalay RN; Mejia-Santana H; Raymond D; Saunders-Pullman R; Roos E; Orbe-Reily M; Tang MX; Mirelman A; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K
    J Genet Couns; 2015 Apr; 24(2):238-46. PubMed ID: 25127731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased prevalence of vertebrobasilar dolichoectasia in Parkinson's disease and its effect on white matter microstructure and network.
    Li S; Zhu Y; Lai H; Da X; Liao T; Liu X; Deng F; Chen L
    Neuroreport; 2024 Jul; 35(10):627-637. PubMed ID: 38813904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A liquid phase based C. elegans behavioral analysis system identifies motor activity loss in a nematode Parkinson's disease model.
    Zheng M; Gorelenkova O; Yang J; Feng Z
    J Neurosci Methods; 2012 Mar; 204(2):234-7. PubMed ID: 22108336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis.
    Menon G; Bakshi S; Krishnan J
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):335-340. PubMed ID: 38334003
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional connectivity and cognitive decline over 3 years in Parkinson disease.
    Olde Dubbelink KT; Schoonheim MM; Deijen JB; Twisk JW; Barkhof F; Berendse HW
    Neurology; 2014 Nov; 83(22):2046-53. PubMed ID: 25355821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resting-state frontostriatal functional connectivity in Parkinson's disease-related apathy.
    Baggio HC; Segura B; Garrido-Millan JL; Marti MJ; Compta Y; Valldeoriola F; Tolosa E; Junque C
    Mov Disord; 2015 Apr; 30(5):671-9. PubMed ID: 25600482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume.
    van Mierlo TJ; Chung C; Foncke EM; Berendse HW; van den Heuvel OA
    Mov Disord; 2015 Feb; 30(2):245-52. PubMed ID: 25600157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral effects of levodopa.
    Beaulieu-Boire I; Lang AE
    Mov Disord; 2015 Jan; 30(1):90-102. PubMed ID: 25491470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment and resting-state network connectivity in Parkinson's disease.
    Baggio HC; Segura B; Sala-Llonch R; Marti MJ; Valldeoriola F; Compta Y; Tolosa E; Junqué C
    Hum Brain Mapp; 2015 Jan; 36(1):199-212. PubMed ID: 25164875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease.
    Ziegler E; Rouillard M; André E; Coolen T; Stender J; Balteau E; Phillips C; Garraux G
    Neuroimage; 2014 Oct; 99():498-508. PubMed ID: 24956065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective.
    Robbins TW; Cools R
    Mov Disord; 2014 Apr; 29(5):597-607. PubMed ID: 24757109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.
    Helmich RC; Thaler A; van Nuenen BF; Gurevich T; Mirelman A; Marder KS; Bressman S; Orr-Urtreger A; Giladi N; Bloem BR; Toni I;
    Neurology; 2015 Jan; 84(4):399-406. PubMed ID: 25540317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered intrinsic brain functional connectivity in drug-naïve Parkinson's disease patients with LRRK2 mutations.
    Hou Y; Luo C; Yang J; Ou R; Song W; Chen Y; Gong Q; Shang H
    Neurosci Lett; 2018 May; 675():145-151. PubMed ID: 29567424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.